Health Technology · Pharmaceuticals: Major · NSE: ANUHPHR · data 2026-10-09
Anuh Pharma Limited
Health check: Strong (7.5/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹82.02
Market cap
₹821 cr
P/E
14.7
P/B
—
ROE
12.1%
ROCE
17.0%
Debt / equity
0
Dividend yield
1.83%
1-year return
1.9%
52-week high
₹99.5
52-week low
₹67
Operating margin
6.9%
Growth
| Revenue (last 12 months) | ₹779 cr |
| Net profit (last 12 months) | ₹44 cr |
| Sales growth, 3 years (yearly) | 13.5% |
| Profit growth, 3 years (yearly) | 4.3% |
Similar companies
Bafna Pharmaceuticals Limited (BAFNAPH) · Shree Ganesh Remedies Ltd. (SGRL) · Kilitch Drugs (India) Limited (KILITCH) · Hexagon Nutrition Limited (HEXAGON) · Amanta Healthcare Limited (AMANTA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ANUHPHR in NSE Scanner →